Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

NCT00001059

Sarcoma, Kaposi HIV Infections

COMPLETED PHASE2

Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00002985

Sarcoma

COMPLETED PHASE3

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00450320

Sarcoma

COMPLETED PHASE1

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

NCT00002147

Sarcoma, Kaposi HIV Infections

COMPLETED PHASE3

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00024024

Sarcoma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the effect of liposomal daunorubicin citrate on Kaposi's sarcoma-associated herpes virus (KSHV) viral gene expression in tumors of patients with HIV-related Kaposi's sarcoma.

Secondary

* Determine the effect of this drug on KSHV viral gene expression in peripheral blood mononuclear cells.
* Determine the effect of this drug on KSHV viral load in plasma.
* Correlate viral load with viral gene expression and/or tumor regression in these patients.

OUTLINE: This is a multicenter, pilot study.

Patients receive liposomal daunorubicin citrate IV days 1 and 15. Treatment repeats every 4 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity.

Biopsies are performed at baseline and once during treatment to evaluate Kaposi's sarcoma- associated herpes virus (KSHV) viral gene expression in tumors and skin tissue using reverse transcriptase-quantitative polymerase chain reaction. Blood samples are collected at baseline and periodically during treatment to evaluate KSHV viral gene expression in peripheral blood mononuclear cells and viral load in plasma.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

liposomal daunorubicin citrate

40 mg/m2 Days 1 and 15 every 28 days x 3 cycles

Group Type EXPERIMENTAL

liposomal daunorubicin citrate

Intervention Type DRUG

40 mg/m2 Days 1 and 15 every 28 days x 3 cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

liposomal daunorubicin citrate

40 mg/m2 Days 1 and 15 every 28 days x 3 cycles

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DaunoXome

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed Kaposi's sarcoma (KS) involving the following:

* Skin
* Lymph nodes (palpable disease only)
* Oral cavity
* Must have ≥ 5 measurable, previously nonirradiated, cutaneous lesions that can be used as indicator lesions
* Must have 2 lesions ≥ 5 x 5 mm that are accessible for 4 mm punch biopsy
* Serologically confirmed HIV positivity
* Concurrent antiretroviral therapy required, except for patients who have exhausted all available treatment options

* Must be on a stable dose for ≥ 4 weeks

PATIENT CHARACTERISTICS:

* Life expectancy ≥ 3 months
* No other neoplasia requiring cytotoxic therapy
* Not pregnant or nursing
* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior anthracycline therapy
* At least 4 weeks since prior antineoplastic treatment for KS, including any of the following:

* Chemotherapy (6 weeks for nitrosoureas or mitomycin C)
* Radiotherapy
* Local therapy
* Biological therapy
* Investigational therapy
* At least 60 days since prior local therapy of any KS indicator lesion unless lesion has clearly progressed since treatment
* No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No